Opportunities for Chemoprevention of Hepatocellular Carcinoma

10:50 - 11:10, Room 104 (104講堂)

Chief, Division of Surgical Oncology, MGH
Deputy Clinical Director, MGH Cancer Center
Director, MGH Liver Surgery Program

Speaker

Professor

Kenneth K. Tanabe
MD

Chair Professor
Graduate Institute of Clinical Medicine
National Taiwan University College of Medicine

Moderator

Professor

Jia-Horng Kao

MD, PhD, FAASLD

高嘉宏 教授

Abstract - 

Opportunities for chemoprevention of hepatocellular carcinoma

     Hepatocellular carcinoma (HCC) occurs far most commonly in the setting of chronic underlying liver disease, a condition that is prevalent in many Asian countries.  China alone accounts for more than 50% of the world’s cases of HCC.  Despite efforts to identify and screen patients at risk for HCC, this cancer is most commonly diagnosed at an advanced stage.  Given the limited effectiveness of therapies for advanced HCC, prevention could have a major impact on global health.  And even in cases in which HCC is diagnosed early and effectively treated, subsequent development of metachronous HCC in the diseased liver is common.  This provides and additional strong rationale for development of an effective agent for HCC prevention.  

     Epidermal growth factor (EGF) is an important mitogen for hepatocytes and overexpression leads to development of HCC in animal models. A single nucleotide polymorphism (SNP) in the 5’ untranslated region of the EGF gene allows for a guanine (G) or adenine (A) in this position of the gene.  This SNP is functional, as the G-containing allele yields EGF RNA transcripts with a longer half-life than transcripts from the A-containing allele.  The G allele correlates with higher EGF in the liver and increased signaling as assessed by liver phospho-EGFR measurements.  And the G allele and higher EGF levels are associated with an increased risk for HCC.  Models for HCC risk that incorporate the EGF SNP status better stratify risk for HCC.  In preclinical models, reduction of EGFR signaling by use of small molecule EGFR inhibitors (e.g. erlotinib) results in improvement of liver function and reduction of risk for HCC.  These encouraging results are being explored in a clinical trial of erlotinib in patients with liver fibrosis or cirrhosis.
 

 

Resecting Unresectable Colorectal Carcinoma Liver Metastases

15:40 - 16:05, Room 104 (104講堂)

Chief, Division of Surgical Oncology, MGH
Deputy Clinical Director, MGH Cancer Center
Director, MGH Liver Surgery Program

Speaker

Professor

Kenneth K. Tanabe
MD

Chairman, Committee of Integration and Development for Advanced Medicine and Biotechnology
E-Da Healthcare Group

Moderator

Professor

Po-Huang Lee

MD, PhD

李伯皇 教授

Abstract - 

Resecting unresectable colorectal carcinoma liver metastases

     The gold standard therapy for management of patients with colorectal carcinoma liver metastases remains surgical resection.  Long term survival is achieved for a subset of patients with colorectal carcinoma liver metastases even after resection of an extensive number of metastases.  The data supporting use of alternative therapies -- which thermal ablation, stereotactic body radiotherapy (SBRT), and internal radiotherapy -- are not as strong as the data supporting resection.  But patients are commonly deemed “unresectable” such that some or all of their liver metastases are managed by one of these alternative therapies.  Common reasons for inappropriately labeling liver metastases as unresectable include tumor involvement of hepatic veins or IVC, bilateral distribution, or inadequate future liver remnant.  Several important surgical techniques have been developed to enable resection of liver tumors in these circumstances. These include creation of a future liver remnant from a single Couinaud liver segment, IVC reconstruction during liver resection, hepatic vein reconstruction during liver resection, and methods to cryopreserve the future liver remnant in situ to allow the time necessary for vascular reconstructions.

台大醫院消化外科國際論壇暨林天祐學術研討會

NTUH International Forum of Digestive Surgery & TY Lin Symposium

2020 台大醫院一般外科忘年會

2020 NTUH General Surgery Celebration Event

Multidisciplinary approach in pancreatic cancer

What

2020一般外科國際論壇暨林天祐學術研討會

When

January 18th, 2020

Where

​台大醫學院 104 講堂

Contact Us

To learn more, don’t hesitate to get in touch

  • White Facebook Icon
  • White Instagram Icon
  • White Twitter Icon
  • White LinkedIn Icon

© 2023 by TIC. Proudly created with Wix.com